FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324302747> ?p ?o ?g. }

• W4324302747 endingPage "e1004196" @default.
• W4324302747 startingPage "e1004196" @default.
• W4324302747 abstract "Current guidelines do not recommend routine antiviral prophylaxis to prevent hepatitis B virus (HBV) reactivation in non-liver solid organ transplant (SOT) recipients with resolved HBV infection, even in anti-hepatitis B surface antigen (anti-HBs)-negative recipients and those receiving intense immunosuppression. This systematic review and meta-analysis aimed to determine the incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver SOT recipients.Three databases (PubMed, Embase, and Cochrane Library) were systematically searched up to December 31, 2022. Clinical studies reporting HBV reactivation in non-liver SOT recipients were included. Case reports, case series, and cohort studies with a sample size of less than 10 patients were excluded. Random-effects analysis was used for all meta-analyses. We included 2,913 non-liver SOT recipients with resolved HBV infection from 16 retrospective cohort studies in the analysis. The overall HBV reactivation rate was 2.5% (76/2,913; 95% confidence interval [95% CI 1.6%, 3.6%]; I2 = 55.0%). Higher rates of reactivation were observed in recipients with negative anti-HBs (34/421; 7.8%; 95% CI [5.2%, 10.9%]; I2 = 36.0%) by pooling 6 studies, experiencing acute rejection (13/266; 5.8%; 95% CI [2.3%, 14.5%]; I2 = 63.2%) by pooling 3 studies, receiving ABO blood type-incompatible transplantation (8/111; 7.0%; 95% CI [2.9%, 12.7%]; I2 = 0%) by pooling 3 studies, receiving rituximab (10/133; 7.3%; 95% CI [3.4%, 12.6%]; I2 = 0%) by pooling 3 studies, and receiving anti-thymocyte immunoglobulin (ATG, 25/504; 4.9%; 95% CI [2.5%, 8.1%]; I2 = 49.0%) by pooling 4 studies. Among recipients with post-transplant HBV reactivation, 11.0% (7/52; 95% CI [4.0%, 20.8%]; I2 = 0.3%) developed HBV-related hepatic failure, and 11.0% (7/52; 95% CI [4.0%, 20.8%]; I2 = 0.3%) had HBV-related death. Negative anti-HBs (crude odds ratio [OR] 5.05; 95% CI [2.83, 9.00]; p < 0.001; I2 = 0%), ABO blood type-incompatible transplantation (crude OR 2.62; 95% CI [1.05, 6.04]; p = 0.040; I2 = 0%), history of acute rejection (crude OR 2.37; 95% CI [1.13, 4.97]; p = 0.022; I2 = 0%), ATG use (crude OR 3.19; 95% CI [1.48, 6.87]; p = 0.003; I2 = 0%), and rituximab use (crude OR 3.16; 95% CI [1.24, 8.06]; p = 0.016; I2 = 0%) increased the risk of reactivation. Adjusted analyses reported similar results. Limitations include moderate heterogeneity in the meta-analyses and that most studies were conducted in kidney transplant recipients.Non-liver SOT recipients with resolved HBV infection have a high risk of HBV-related hepatic failure and HBV-related death if HBV reactivation occurs. Potential risk factors for HBV reactivation include rituximab use, anti-thymocyte immunoglobulin use, anti-HBs negative status, acute rejection history, and ABO blood type-incompatible transplantation. Further research on monitoring and routine antiviral prophylaxis of non-liver SOT recipients at higher risk of HBV reactivation is required." @default.
• W4324302747 created "2023-03-16" @default.
• W4324302747 creator A5010882331 @default.
• W4324302747 creator A5025571591 @default.
• W4324302747 creator A5049416052 @default.
• W4324302747 creator A5053447705 @default.
• W4324302747 creator A5091902498 @default.
• W4324302747 date "2023-03-15" @default.
• W4324302747 modified "2023-09-22" @default.
• W4324302747 title "Incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver solid organ transplant recipients with resolved HBV infection: A systematic review and meta-analysis" @default.
• W4324302747 cites W1994351795 @default.
• W4324302747 cites W2003831013 @default.
• W4324302747 cites W2019608694 @default.
• W4324302747 cites W2020197733 @default.
• W4324302747 cites W2047232371 @default.
• W4324302747 cites W2064167438 @default.
• W4324302747 cites W2068521915 @default.
• W4324302747 cites W2077165978 @default.
• W4324302747 cites W2091851863 @default.
• W4324302747 cites W2092588192 @default.
• W4324302747 cites W2107328434 @default.
• W4324302747 cites W2122971756 @default.
• W4324302747 cites W2147134417 @default.
• W4324302747 cites W2148210417 @default.
• W4324302747 cites W2148361291 @default.
• W4324302747 cites W2156098321 @default.
• W4324302747 cites W2166132400 @default.
• W4324302747 cites W2582667894 @default.
• W4324302747 cites W2597520839 @default.
• W4324302747 cites W2683912726 @default.
• W4324302747 cites W2751262242 @default.
• W4324302747 cites W2756936577 @default.
• W4324302747 cites W2795556933 @default.
• W4324302747 cites W2801005253 @default.
• W4324302747 cites W2896010817 @default.
• W4324302747 cites W2896957412 @default.
• W4324302747 cites W2918459001 @default.
• W4324302747 cites W2991792334 @default.
• W4324302747 cites W2996396683 @default.
• W4324302747 cites W3005970435 @default.
• W4324302747 cites W3010313192 @default.
• W4324302747 cites W3015680166 @default.
• W4324302747 cites W3193789330 @default.
• W4324302747 cites W3208266438 @default.
• W4324302747 cites W4211026375 @default.
• W4324302747 cites W4211117577 @default.
• W4324302747 cites W4235469095 @default.
• W4324302747 cites W4235562038 @default.
• W4324302747 doi "https://doi.org/10.1371/journal.pmed.1004196" @default.
• W4324302747 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36920988" @default.
• W4324302747 hasPublicationYear "2023" @default.
• W4324302747 type Work @default.
• W4324302747 citedByCount "0" @default.
• W4324302747 crossrefType "journal-article" @default.
• W4324302747 hasAuthorship W4324302747A5010882331 @default.
• W4324302747 hasAuthorship W4324302747A5025571591 @default.
• W4324302747 hasAuthorship W4324302747A5049416052 @default.
• W4324302747 hasAuthorship W4324302747A5053447705 @default.
• W4324302747 hasAuthorship W4324302747A5091902498 @default.
• W4324302747 hasBestOaLocation W43243027471 @default.
• W4324302747 hasConcept C120665830 @default.
• W4324302747 hasConcept C121332964 @default.
• W4324302747 hasConcept C126322002 @default.
• W4324302747 hasConcept C167135981 @default.
• W4324302747 hasConcept C203014093 @default.
• W4324302747 hasConcept C2522874641 @default.
• W4324302747 hasConcept C2777382497 @default.
• W4324302747 hasConcept C2779609443 @default.
• W4324302747 hasConcept C2780252810 @default.
• W4324302747 hasConcept C2780593183 @default.
• W4324302747 hasConcept C2911091166 @default.
• W4324302747 hasConcept C61511704 @default.
• W4324302747 hasConcept C71924100 @default.
• W4324302747 hasConcept C90924648 @default.
• W4324302747 hasConcept C95190672 @default.
• W4324302747 hasConceptScore W4324302747C120665830 @default.
• W4324302747 hasConceptScore W4324302747C121332964 @default.
• W4324302747 hasConceptScore W4324302747C126322002 @default.
• W4324302747 hasConceptScore W4324302747C167135981 @default.
• W4324302747 hasConceptScore W4324302747C203014093 @default.
• W4324302747 hasConceptScore W4324302747C2522874641 @default.
• W4324302747 hasConceptScore W4324302747C2777382497 @default.
• W4324302747 hasConceptScore W4324302747C2779609443 @default.
• W4324302747 hasConceptScore W4324302747C2780252810 @default.
• W4324302747 hasConceptScore W4324302747C2780593183 @default.
• W4324302747 hasConceptScore W4324302747C2911091166 @default.
• W4324302747 hasConceptScore W4324302747C61511704 @default.
• W4324302747 hasConceptScore W4324302747C71924100 @default.
• W4324302747 hasConceptScore W4324302747C90924648 @default.
• W4324302747 hasConceptScore W4324302747C95190672 @default.
• W4324302747 hasIssue "3" @default.
• W4324302747 hasLocation W43243027471 @default.
• W4324302747 hasLocation W43243027472 @default.
• W4324302747 hasLocation W43243027473 @default.
• W4324302747 hasOpenAccess W4324302747 @default.
• W4324302747 hasPrimaryLocation W43243027471 @default.
• W4324302747 hasRelatedWork W2012677482 @default.
• W4324302747 hasRelatedWork W2049302023 @default.

• next